An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Therapeutic Solutions International Recruits Dr. Donald Banerji to Scientific Advisory Board
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
management
Rhea-AI Summary
Therapeutic Solutions International announced the appointment of Dr. Donald Banerji to its Scientific Advisory Board. Dr. Banerji, a leader in respiratory medicine with over 33 years of experience, will provide guidance as the company advances its Phase III clinical trial for COVID-19 and has filed an Investigational New Drug Application for Chronic Obstructive Pulmonary Disease (COPD). CEO Timothy Dixon highlighted Dr. Banerji's extensive expertise in the development of drugs for respiratory conditions as crucial for the company's transition to a clinical-stage organization.
Positive
Dr. Donald Banerji's appointment brings significant expertise in respiratory medicine to the advisory board.
His experience includes FDA approval for 14 drugs, potentially benefiting TSOI's ongoing clinical trials.
The timing of his appointment aligns with TSOI's Phase III clinical trial for COVID-19, likely enhancing its credibility and development.
Negative
None.
Former Head of Novartis Respiratory and Allergy Medicine to Advise Clinical Stage Stem Cell Company on COVID-19 and COPD Programs
OCEANSIDE, Calif.--(BUSINESS WIRE)--
Therapeutic Solutions International announced today the appointment of Dr. Donald Banerji to the Company’s Scientific Advisory Board.
Dr. Banerji joins internationally renowned opinion leaders including Dr. Santosh Kesari, Chair of Department of Translational Neuro-Oncology and Neurotherapeutics at the John Wayne Cancer Institute, Dr. Francesco Marincola, Global Head of Cell Therapy Research at Kite Therapeutics (owned by Gilead), Dr. Boris Minev, President of Calidi Biotherapeutics, and Dr. Boris Reznik, Chairman of Venvalo Group.
“I am pleased to welcome Dr. Banerji to our Scientific Advisory Board. His addition is perfectly timed as the Company is conducting a Phase III clinical trial in advanced COVID-19 patients1 and has recently filed an Investigational New Drug Application (IND) for treatment of Chronic Obstructive Pulmonary Disease (COPD)2,” said Timothy Dixon, President and Chief Executive Officer of the Company. “Our transition from a preclinical to a clinical stage organization requires domain-specific expertise and insight. Given that Dr. Banerji has obtained FDA approval for commercialization of 14 novel drugs in respiratory medicine, we believe his expertise is second to none.”
“Success in the area of regenerative medicine requires deep knowledge of the complicated scientific, biological and clinical issues associated with developing a ‘living drug’. I look forward to leveraging my previous experiences and contacts in the area of respiratory medicine to accelerate the progress of the Company in making an impact in the areas of COVID-19 and COPD, for which currently no regenerative approaches exist,” said Dr. Banerji.
Dr. Banerji is a Physician-Scientist with 33 years of Global Development and management experience in Pulmonary Drug Development, has led approvals and launch of 14 FDA approved drugs worldwide in COPD, Asthma and Allergic Rhinitis. Dr. Banerji has published over 100 original articles (The Ultibro story!) in peer reviewed journals (FLAME:NEJM) and over 400 abstracts, with presentations at major International Congress's. The recipient of multiple Novartis scientific awards at the Development (Hero of Development) Pharma (Leading Scientist) and Corporate (Distinguished Scientist) levels including Business Excellence awards. He is the only Novartis Physician-Scientist and only Clinician in Global Drug Development to be recognized twice (2014, Leading Scientist; 2016, Distinguished Scientist) with the prestigious Novartis VIVA (Vision, Innovation, Value and Achievement) Awards which represents the highest scientific achievement in Novartis.
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.
Who is Dr. Donald Banerji in relation to Therapeutic Solutions International?
Dr. Donald Banerji has been appointed to the Scientific Advisory Board of Therapeutic Solutions International, bringing extensive expertise in respiratory medicine.
What is the significance of Dr. Banerji's appointment for TSOI?
His appointment is significant as it coincides with TSOI's Phase III clinical trial for COVID-19, potentially aiding in the drug development process.
What are TSOI's current clinical trials related to?
TSOI is currently conducting a Phase III clinical trial focused on advanced COVID-19 patients and has filed for an IND for COPD treatment.
